NCT06422884
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 21 versions: 21 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 32 words Show 4 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Oct 2026 to Aug 21, 2026
- Secondary endpoints: details revised at 6 of 11 entries
- Site details revised at 2 of 78 sites
Notable Primary endpoint revisedv20 Show 4 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 200 to confirmed 213
- Study sites: 81 to 78
- Secondary endpoints: 9 to 11
- Minor Site details revised at 9 of 81 sitesv19
- Minor Site details revised at 7 of 81 sitesv18
- Minor Site details revised at 3 of 81 sitesv17
Show 15 earlier versionsHide 15 earlier versions
- Minor Site details revised at 5 of 81 sitesv16
- Minor Site details revised at 1 of 81 sitesv15
- Minor Site details revised at 6 of 81 sitesv14
- Minor Site details revised at 3 of 81 sitesv13
- Minor Study sites: 80 to 81v12
- Minor Site details revised at 3 of 80 sitesv11
- Minor Site details revised at 3 of 80 sitesv10
- Minor Site details revised at 14 of 80 sitesv9
- Minor Site details revised at 2 of 80 sitesv8
- Minor Site details revised at 6 of 80 sitesv7
- Minor Study sites: 78 to 80
- Primary and study completion dates: Jun 2026 to Oct 2026
- Minor Study sites: 66 to 78v5
- Minor Study sites: 64 to 66v4
- Minor Study sites: 41 to 64v3
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 8 more changesShow less
- Enrollment target: 320 to 200
- Eligibility criteria shortened, about 30 words
- Primary endpoints: 2 to 1
- Study sites: 42 to 41
- Start date changed from estimate of Sep 2024 to Nov 15, 2024
- Secondary endpoints: 10 to 9
- Study description shortened, about 14 words
- Study arms: 8 to 4
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in percent predicted forced vital capacity (ppFVC) compared to placebo
Timeframe: Baseline and Week 24
Secondary (11)
Absolute change in FVC (mL) compared to placebo
Time to disease progression (absolute decline in ppFVC >10%, IPF-related hospitalization, or death) compared to placebo
Absolute change in the Living with Pulmonary Fibrosis Symptoms (L-PF Symptoms) Questionnaire Cough domain score compared to placebo
Absolute change in the L-PF Symptoms Questionnaire Dyspnea domain score compared to placebo
Absolute change in the L-PF Symptoms Questionnaire Fatigue domain score compared to placebo
Show 6 moreShow less
Absolute change in the L-PF Symptoms module score compared to placebo
Absolute change in the L-PF Impacts module score compared to placebo
Absolute change in total lung capacity (TLC) by chest high-resolution computed tomography (HRCT) imaging compared to placebo
Absolute change in % quantitative interstitial lung disease (QILD) by chest HRCT imaging compared to placebo compared to placebo
Absolute change in % quantitative ground glass opacity (QGG) by chest HRCT imaging compared to placebo
Absolute change in % quantitative lung fibrosis (QLF) by chest HRCT imaging compared to placebo
Arms and interventions
ENV-101 Low Dose (IPF Population)Experimental
ENV-101 Mid Dose (IPF Population)Experimental
ENV-101 High Dose (IPF Population)Experimental
Placebo (IPF Population)Placebo comparator
Drugs: ENV-101, Placebo
Sites
78 sites in 14 countries
France 10, United Kingdom 9, Mexico 8, South Korea 7, Australia 6, Canada 6, Germany 6, Italy 6, Argentina 5, Ireland 4, Belgium 3, Malaysia 3, New Zealand 3, Austria 2